Aurinia Pharmaceuticals (AUPH) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Vera Therapeutics (VERA) over the past year, gaining 36.7% versus a loss of 1.8%. Over five years, VERA leads with a +101.5% price change compared with -22.2% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($2.11 billion vs $2.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | VERA |
|---|---|---|
| Share price | $15.90 | $29.17 |
| Market cap | $2.11B | $2.10B |
| 1-day change | -0.72% | -3.58% |
| YTD return | +0.38% | -40.26% |
| 1-year return | +36.72% | -1.79% |
| 5-year return | -22.17% | +101.53% |
| P/E ratio (TTM) | 6.97 | — |
| Forward P/E | 14.90 | — |
| EPS (TTM) | $2.28 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.25 | $56.05 |
| 52-week low | $10.90 | $23.05 |
| Distance from 52-week high | -17.43% | -47.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +12.36% | +165.71% |
| Average volume | 988.90K | 2.23M |
| Shares outstanding | 133.05M | 72.06M |
| Employees | 128 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed VERA by 38.5 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
AUPH vs VERA FAQ
Which is bigger, Aurinia Pharmaceuticals or Vera Therapeutics?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.11B compared with $2.10B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, AUPH or VERA?
AUPH returned +36.72% over the past 12 months, compared with -1.79% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.